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P H Y S I O L O G Y
Gene therapy for follistatin mitigates systemic 
metabolic inflammation and post-traumatic arthritis 
in high-fat diet–induced obesity
Ruhang Tang1,2,3, Natalia S. Harasymowicz1,2,3, Chia-Lung Wu1,2,3, Kelsey H. Collins1,2,3,  
Yun-Rak Choi1,2,3,4, Sara J. Oswald1,2,3, Farshid Guilak1,2,3*
Obesity-associated inflammation and loss of muscle function play critical roles in the development of osteoarthritis 
(OA); thus, therapies that target muscle tissue may provide novel approaches to restoring metabolic and bio-
mechanical dysfunction associated with obesity. Follistatin (FST), a protein that binds myostatin and activin, may 
have the potential to enhance muscle formation while inhibiting inflammation. Here, we hypothesized that adeno- 
associated virus 9 (AAV9) delivery of FST enhances muscle formation and mitigates metabolic inflammation and 
knee OA caused by a high-fat diet in mice. AAV-mediated FST delivery exhibited decreased obesity-induced in-
flammatory adipokines and cytokines systemically and in the joint synovial fluid. Regardless of diet, mice receiving 
FST gene therapy were protected from post-traumatic OA and bone remodeling induced by joint injury. Together, 
these findings suggest that FST gene therapy may provide a multifactorial therapeutic approach for injury-induced 
OA and metabolic inflammation in obesity.
INTRODUCTION
Osteoarthritis (OA) is a multifactorial family of diseases, characterized 
by cartilage degeneration, joint inflammation, and bone remodel-
ing. Despite the broad impact of this condition, there are currently 
no disease-modifying drugs available for OA. Previous studies demon-
strate that obesity and dietary fatty acids (FAs) play a critical role in 
the development of OA, and metabolic dysfunction secondary to 
obesity is likely to be a primary risk factor for OA (1), particularly 
following joint injury (2, 3). Furthermore, both obesity and OA are 
associated with a rapid loss of muscle integrity and strength (4), which 
may contribute directly and indirectly to the onset and progression 
of OA (5). However, the mechanisms linking obesity, muscle, and 
OA are not fully understood and appear to involve interactions among 
biomechanical, inflammatory, and metabolic factors (6). Therefore, 
strategies that focus on protecting muscle and mitigating metabolic 
inflammation may provide an attractive target for OA therapies in 
this context.
A few potential interventions, such as weight loss and exercise, 
have been proposed to reverse the metabolic dysfunction associated 
with obesity by improving the quantity or quality of skeletal muscle 
(7). Skeletal muscle mass is modulated by myostatin, a member of 
the transforming growth factor– (TGF-) superfamily and a potent 
negative regulator of muscle growth (8), and myostatin is up-regulated 
in obesity and down-regulated by exercise (9). While exercise and weight 
loss are the first line of therapy for obesity and OA, several studies 
have shown difficulty in achieving long-term maintenance of weight 
loss or strength gain, particularly in frail or aging populations (10). 
Thus, targeted pharmacologic or genetic inhibition of muscle-regulatory 
molecules such as myostatin provides a promising approach to im-
proving muscle metabolic health by increasing glucose tolerance and 
enhancing muscle mass in rodents and humans (8).
Follistatin (FST), a myostatin- and activin-binding protein, has 
been used as a therapy for several degenerative muscle diseases (11, 12), 
and loss of FST is associated with reduced muscle mass and prenatal 
death (13). In the context of OA, we hypothesize that FST delivery 
using a gene therapy approach has multifactorial therapeutic potential 
through its influence on muscle growth via inhibition of myostatin 
activity (14) as well as other members of the TGF- family. More-
over, FST has been reported to reduce the infiltration of inflammatory 
cells in the synovial membrane (15) and affect bone development 
(16), and pretreatment with FST has been shown to reduce the se-
verity of carrageenan-induced arthritis (15). However, the potential 
for FST as an OA therapy has not been investigated, especially in 
exacerbating pathological conditions such as obesity. We hypothe-
sized that overexpression of FST using a gene therapy approach will 
increase muscle mass and mitigate obesity-associated metabolic in-
flammation, as well as the progression of OA, in high-fat diet (HFD)– 
induced obese mice. Mice fed an HFD were treated with a single 
dose of adeno-associated virus 9 (AAV9) to deliver FST or a green 
fluorescent protein (GFP) control, and the effects on systemic meta-
bolic inflammation and post-traumatic OA were studied (fig. S1).
RESULTS
FST gene therapy prevents HFD-induced obesity 
and inflammation
Dual-energy x-ray absorptiometry (DXA) imaging of mice at 26 weeks 
of age (Fig. 1A) showed significant effects of FST treatment on body 
composition. Control-diet, FST-treated mice (i.e., Control-FST mice) 
exhibited significantly lower body fat percentages, but were signifi-
cantly heavier than mice treated with a GFP control vector (Control- 
GFP mice) (Fig. 1B), indicating that increased muscle mass rather 
than fat was developed with FST. With an HFD, control mice (HFD- 
GFP mice) showed significant increases in weight and body fat per-
centage that were ameliorated by FST overexpression (HFD-FST mice).
In the HFD group, overexpression of FST significantly decreased 
serum levels of several adipokines including insulin, leptin, resistin, 
and C-peptide as compared to GFP-treated mice (Fig. 1C). HFD-FST 
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mice also had significantly lower serum levels of glucose, triglycerides, 
cholesterol, and free FAs (FFAs) (Fig. 1D), as well as the inflammatory 
cytokine interleukin-1 (IL-1) (Fig. 1E) when compared to HFD-GFP 
mice. For both dietary groups, AAV-FST delivery significantly increased 
circulating levels of vascular endothelial growth factor (VEGF) while 
significantly decreasing IL-1 levels. Furthermore, obesity- induced 
inflammation in adipose tissue was verified by the presence of CD11b+ 
CD11c+ M1 pro-inflammatory macrophages or dendritic cells (Fig. 1F).
FST gene therapy mitigates OA severity and restores muscle 
performance and pain sensitivity in HFD-fed mice
To determine whether FST gene therapy can mitigate injury-induced 
OA, mice underwent surgery for destabilization of the medial me-
niscus (DMM) and were sacrificed 12 weeks after surgery. Cartilage 
degeneration was significantly reduced in DMM joints of the mice 
receiving FST gene therapy in both dietary groups (Fig. 2, A and C) 
when compared to GFP controls. FST overexpression also signifi-
cantly decreased joint synovitis (Fig. 2, B and D) when compared to 
GFP controls. To evaluate the local influence of pro-inflammatory 
cytokines to joint degeneration and inflammation, synovial fluid (SF) 
was harvested from surgical and ipsilateral nonsurgical limbs 
and analyzed using a multiplexed array. The DMM joints from 
mice with FST overexpression exhibited a trend toward lower levels 
of pro-inflammatory cytokines, including IL-1, IL-1, and IL-6, 
and a higher level of interferon- (IFN-)–induced protein (IP-10) 
in the SF of DMM joints as compared to contralateral controls (Fig. 2E).
Fig. 1. Effects of AAV-mediated FST delivery on body composition and systemic inflammatory markers. (A) DXA images of mice at 26 weeks of age. (B) DXA mea-
surements of body fat percentage and bone mineral density (BMD; 26 weeks) and body weight measurements over time. (C) Serum levels for adipokines (insulin, leptin, 
resistin, and C-peptide) at 28 weeks. (D) Metabolite levels for glucose, triglycerides, cholesterol, and FFAs at 28 weeks. (E) Serum levels for cytokines (IL-1, IL-1, 
MCP-1, and VEGF) at 28 weeks. (F) Fluorescence microscopy images of visceral adipose tissue with CD11b:Alexa Fluor 488 (green), CD11c:phycoerythrin (PE) (red), and 
4′,6-diamidino-2-phenylindole (DAPI; blue). Scale bars, 100 m. Data are presented as mean ± SEM; n = 8 to 10; two-way analysis of variance (ANOVA), P < 0.05. Groups not 
sharing the same letter are significantly different with Tukey post hoc analysis. For IL-1 and VEGF, P < 0.05 for diet effect and AAV effect. For MCP-1, P < 0.05 for diet effect.
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To investigate the effect of FST on pain sensitivity in OA, animals 
were subjected to a variety of pain measurements including hot plate, 
cold plate, and algometry. Obesity increased heat withdrawal latency, 
which was rescued by FST overexpression (Fig. 2F). Cold sensitivity 
trended lower with obesity, and because no significant differences 
in heat withdrawal latency were found with surgery (fig. S2), no cold 
sensitivity was measured after surgery. We found that FST treatment 
protected HFD animals from mechanical algesia at the knee receiving 
DMM surgery, while Control-diet DMM groups demonstrated in-
creased pain sensitivity following joint injury.
A bilinear regression model was used to elucidate the relation-
ship among OA severity, biomechanical factors, and metabolic factors 
Fig. 2. Effects of AAV-FST delivery on OA severity, synovitis, inflammatory cytokines, and pain. (A) Histologic analysis of OA severity via Safranin O (glycosaminoglycans) 
and fast green (bone and tendon) staining of DMM-operated joints. (B) Histology [hematoxylin and eosin (H&E) staining] of the medial femoral condyle of DMM- operated 
joints. Thickened synovium (S) from HFD mice with a high density of infiltrated cells was observed (arrows). (C) Modified Mankin scores compared within the diet. 
(D) Synovitis scores compared within the diet. (E) Levels of proinflammatory cytokines in the SF compared within the diet. (F) Hot plate latency time and sensitivity to cold 
plate exposure, as measured using the number of jumps in 30 s, both for non-operated algometry measurements of pain sensitivity compared within the diet. Data are 
presented as mean ± SEM; n = 5 to 10 mice per group; two-way ANOVA, P < 0.05. Groups not sharing the same letter are significantly different with Tukey post hoc analysis.
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(table S1). Factors significantly correlated with OA were then selected 
for multivariate regression (Table 1). Both multivariate regression 
models revealed serum tumor necrosis factor- (TNF-) levels as a 
major predictor of OA severity.
FST gene therapy enhances muscle growth and restores 
muscle performance in HFD-fed mice
We analyzed the effects of FST treatment on muscle structure and 
mass, and performance measures were conducted on mice in both 
dietary groups. Both Control-FST and HFD-FST limbs exhibited 
visibly larger muscles compared to both AAV-GFP groups (Fig. 3A). 
In addition, the muscle masses of tibialis anterior (TA), gastrocnemius, 
and quadriceps increased significantly with FST treatment (Fig. 3B). 
Western blot analysis confirmed an increase in FST expression in 
the muscle at the protein level in FST-treated groups compared to 
GFP-treated animals in Control and HFD groups (Fig. 3C). Immuno-
fluorescence labeling showed increased expression of FST in muscle 
(Fig. 3D) and adipose tissue (Fig. 3E) of the AAV-FST mice, with 
little or no expression of FST in control groups.
To determine whether the increases in muscle mass reflected 
muscle hypertrophy, gastrocnemius muscle fiber diameter was mea-
sured in H&E-stained sections (Fig. 3F) at 28 weeks of age. Mice 
with FST overexpression exhibited increased fiber diameter (i.e., 
increased muscle hypertrophy) relative to the GFP-expressing mice 
in both diet treatments (Fig. 3G). Oil Red O staining was used to 
determine the accumulation of neutral lipids in muscle (Fig. 3H). 
We found that HFD-FST mice were protected from lipid accumulation 
in muscles compared to HFD-GFP mice (Fig. 3I). Second-harmonic 
generation imaging confirmed the presence of increased collagen 
content in the muscles of HFD mice, which was prevented by FST 
gene therapy (Fig. 3J). We also examined the expression and phos-
phorylation levels of the key proteins responsible for insulin signal-
ing in muscles. We observed increased phosphorylation of AktS473, 
S6KT389, and S6RP-S235/2369 and higher expression of peroxisome 
proliferator–activated receptor  coactivator 1- (Pgc1-) in muscles 
from FST mice compared to GFP mice, regardless of diet (Fig. 3K). 
In addition to the improvements in muscle structure with HFD, 
FST-overexpressing mice also showed improved function, includ-
ing higher grip strength and increased treadmill running endurance 
(Fig. 3L), compared to GFP mice.
Because FST has the potential to influence cardiac muscle and 
skeletal muscle, we performed a detailed evaluation on the effect 
of FST overexpression on cardiac function. Echocardiography and 
short-axis images were collected to visualize the left ventricle (LV) 
movement during diastole and systole (fig. S3A). While the Control- 
FST mice had comparable LV mass (LVM) and left ventricular pos-
terior wall dimensions (LVPWD) with Control-GFP mice (fig. S3, B 
and C), the HFD-FST mice have significantly decreased LVM and 
trend toward decreased LVPWD compared to HFD-GFP. Regard-
less of the diet treatments, FST overexpression enhanced the rate of 
heart weight/body weight (fig. S3D). Although Control-FST mice 
had slightly increased dimensions of the interventricular septum at 
diastole (IVSd) compared to Control-GFP (fig. S3E), there was sig-
nificantly lower IVSd in HFD-FST compared to HFD-GFP. In ad-
dition, we found no difference in fractional shortening among all 
groups (fig. S3F). Last, transmitral blood flow was investigated us-
ing pulse Doppler. While there was no difference in iso-volumetric 
relaxation time (IVRT) in Control groups, HFD-FST mice had a mod-
erate decrease in IVRT compared to HFD-GFP (fig. S3G). Overall, 
FST treatment mitigated the changes in diastolic dysfunction and 
improved the cardiac relaxation caused by HFD.
FST gene therapy protects trabecular and cortical bone 
microstructure following injury or HFD
DXA demonstrated that FST gene therapy improved bone mineral 
density (BMD) in HFD compared to other groups (Fig. 1B). To de-
termine the effects of injury, diet intervention, and overexpression 
of FST on bone morphology, knee joints were evaluated by micro-
computed tomography (microCT) (Fig. 4A). The presence of het-
erotopic ossification was observed throughout the GFP knee joints, 
whereas FST groups demonstrated a reduction or an absence of 
heterotopic ossification. FST overexpression significantly increased 
the ratio of bone volume to total volume (BV/TV), BMD, and tra-
becular number (Tb.N) of the tibial plateau in animals, regardless of 
diet treatment (Fig. 4B). Joint injury generally decreased bone pa-
rameters in the tibial plateau, particularly in Control-diet mice. In 
the femoral condyle, BV/TV and Tb.N were significantly increased 
in mice with FST overexpression in both diet types, while BMD was 
significantly higher in HFD-FST compared to HFD-GFP mice 
(Fig. 4B). Furthermore, AAV-FST delivery significantly increased 
trabecular thickness (Tb.Th) and decreased trabecular space (Tb.
Sp) in the femoral condyle of HFD-FST compared to HFD-GFP an-
imals (fig. S4).
Further microCT analysis was conducted on the trabecular (Fig. 4C) 
and cortical (Fig. 4E) areas of the metaphyses. FST gene therapy sig-
nificantly increased BV/TV, Tb.N, and BMD in the metaphyses re-
gardless of the diet (Fig. 4D). Furthermore, FST delivery significantly 
increased the cortical cross-sectional thickness (Ct.Cs.Th) and polar 
moment of inertia (MMI) of mice on both diet types, as well as tis-
sue mineral density (TMD) of cortical bones of mice fed control diet 
(Fig. 4F).
FST gene therapy promotes browning of WAT and rescues 
mitochondrial oxidative phosphorylation
To elucidate the possible mechanisms by which FST mitigates in-
flammation, we examined the browning/beiging process in sub-
cutaneous adipose tissue (SAT) with immunohistochemistry (Fig. 5A). 
Here, we found that key proteins expressed mainly in brown adipose 
tissue (BAT) (PGC-1, PRDM16, thermogenesis marker UCP-1, and 
beige adipocyte marker CD137) were up-regulated in SAT of the mice 
with FST overexpression (Fig. 5B). Increasing evidence suggests that 
Table 1. Multivariate regression analyses for factors predicting OA 
severity. , standardized coefficient. ***P < 0.001. 
Predictor variables Model 1
Model 2

SF IL-1 0.13 0.003
Serum IL-1 0.006 0.073
Serum TNF- 0.471 0.537
Serum amylin 0.023 0.026
Body fat percentage 0.142 –
Serum leptin – 0.00003
Adjusted r2 0.613*** 0.379***
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an impaired mitochondrial oxidative phosphorylation (OXPHOS) 
system in white adipocytes is a hallmark of obesity-associated 
inflammation (17). Therefore, we further examined the mitochondrial 
respiratory system in SAT. HFD reduced the amount of OXPHOS 
complex subunits (Fig. 5C). We found that proteins involved 
in OXPHOS, including subunits of complexes I, II, and III of 
mitochondria OXPHOS complex, were significantly up-regulated 
in AAV-FST–overexpressing animals compared to AAV-GFP 
mice (Fig. 5D).
DISCUSSION
Our findings demonstrate that a single injection of AAV-mediated 
FST gene therapy ameliorated systemic metabolic dysfunction and 
mitigated OA-associated cartilage degeneration, synovial inflamma-
tion, and bone remodeling occurring with joint injury and an HFD. 
Of note, the beneficial effects were observed across multiple tissues 
of the joint organ system, underscoring the value of this potential 
treatment strategy. The mechanisms by which obesity and an HFD 
increase OA severity are complex and multifactorial, involving 
Fig. 3. Effects of AAV-FST gene therapy on muscle structure and function. (A) Photographic images and (B) measured mass of tibialis anterior (TA), gastrocnemius (GAS), 
and quadriceps (QUAD) muscles; n = 8, diet and AAV effects both P < 0.05. (C) Western blot showing positive bands of FST protein only in FST-treated muscles, with -actin 
as a loading control. Immunolabeling of (D) GAS muscle and (E) adipose tissue showing increased expression of FST, particularly in skeletal muscle. (F) H&E-stained sec-
tions of GAS muscles were measured for (G) mean myofiber diameter; n = 100 from four mice per group, diet, and AAV effects; both P < 0.05. (H) Oil Red O staining was 
analyzed for (I) optical density values of FAs; n = 6. (J) Second-harmonic generation imaging of collagen in TA sections was quantified for intensity; n = 6. (K) Western 
blotting showing the level of phosphorylation markers of protein synthesis in GAS muscle. (L) Functional analysis of grip strength and treadmill time to exhaustion; n = 10. 
Data are presented as mean ± SEM; two-way ANOVA, P < 0.05. Groups not sharing the same letter are significantly different with Tukey post hoc analysis. Photo credit: 
Ruhang Tang, Washington University.
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increased systemic metabolic inflammation, joint instability and loss 
of muscle strength, and synergistic interactions between local and 
systemic cytokines (4, 6). In this regard, the therapeutic consequences 
of FST gene therapy also appear to be multifactorial, involving both 
direct and indirect effects such as increased muscle mass and meta-
bolic activity to counter caloric intake and metabolic dysfunction 
resulting from an HFD while also promoting adipose tissue brown-
ing. Furthermore, FST may also serve as a direct inhibitor of growth 
factors in the TGF- family that may be involved in joint degenera-
tion (18).
FST gene therapy showed a myriad of notable beneficial effects 
on joint degeneration following joint injury while mitigating HFD- 
induced obesity. These data also indirectly implicate the critical role 
of muscle integrity in the onset and progression of post-traumatic 
Fig. 4. Effects of AAV-FST gene delivery on bone structure. (A) Three-dimensional (3D) reconstruction of microCT images of non-operated and DMM-operated knees. 
(B) Tibial plateau (TP) and femoral condyle (FC) regional analyses of trabecular bone fraction bone volume (BV/TV), BMD, and trabecular number (Tb.N). Data are presented 
as mean ± SEM; n = 8 to 19 mice per group; two-way ANOVA. (C) 3D microCT reconstruction of metaphysis region of DMM-operated joints. (D) Analysis of metaphysis BV/TV, 
Tb.N, and BMD. (E) 3D microCT reconstruction of cortical region of DMM-operated joints. (F) Analysis of cortical cross-sectional thickness (Ct.Cs.Th), polar moment of 
inertia (MMI), and tissue mineral density (TMD). (D and F) Data are presented as mean ± SEM; n = 8 to 19 mice per group; Mann-Whitney U test, *P < 0.05.
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OA in this model. It is important to note that FST gene therapy 
mitigated many of the key negative phenotypic changes previously 
associated with obesity and OA, including cartilage structural changes 
as well as bone remodeling, synovitis, muscle fibrosis, and increased 
pain, as compared to GFP controls. To minimize the number of 
animals used, we did not perform additional controls with no AAV 
delivery; however, our GFP controls showed similar OA changes as 
observed in our previous studies, which did not involve any gene 
delivery (2). Mechanistically, FST restored to control levels a num-
ber of OA-associated cytokines and adipokines in the serum and 
the SF. While the direct effects of FST on chondrocytes remains to 
be determined, FST has been shown to serve as a regulator of the 
endochondral ossification process during development (19), which 
may also play a role in OA (20). Furthermore, previous studies have 
shown that a 2-week FST treatment of mouse joints is beneficial in 
reducing infiltration of inflammatory cells into the synovial membrane 
(15). Our findings suggest that FST delivery in skeletally mature mice, 
preceding obesity-induced OA changes, substantially reduces the prob-
ability of tissue damage.
It is well recognized that FST can inhibit the activity of myostatin 
and activin, both of which are up-regulated in obesity-related mo-
dalities and are involved in muscle atrophy, tissue fibrosis, and in-
flammation (21). Consistent with previous studies, our results show 
that FST antagonizes the negative regulation of myostatin in muscle 
growth, reducing adipose tissue content in animals. Our observation 
that FST overexpression decreased inflammation at both serum sys-
temic and local joint inflammation may provide mechanistic insights 
into our findings of mitigated OA severity in HFD-fed mice. Our sta-
tistical analysis implicated serum TNF- levels as a major factor in 
OA severity, consistent with previous studies linking obesity and 
OA in mice (22). Although the precise molecular mechanisms of FST 
in modulating inflammation remain unclear, some studies postulate 
that FST may act like acute-phase protein in lipopolysaccharide- 
induced inflammation (23).
In addition to these effects of skeletal muscle, we found that FST 
gene therapy normalized many of the deleterious changes of an HFD 
on cardiac function without causing hypertrophy. These findings 
are consistent with previous studies showing that, during the process 
of aging, mice with myostatin knockout had an enhanced cardiac 
stress response (24). Furthermore, FST has been shown to regulate 
activin-induced cardiomyocyte apoptosis (1). In the context of this 
study, it is also important to note that OA has been shown to be a 
serious risk factor for progression of cardiovascular disease (25), 
and severity of OA disability is associated with significant increases 
in all-cause mortality and cardiovascular events (26).
FST gene therapy also rescued diet- and injury-induced bone re-
modeling in the femoral condyle, as well as the tibial plateau, me-
taphysis, and cortical bone of the tibia, suggesting a protective effect 
of FST on bone homeostasis of mice receiving an HFD. FST is a known 
inhibitor of bone morphogenetic proteins (BMPs), and thus, the in-
teraction between the two proteins plays an essential role during 
bone development and remodeling. For example, mice grown with 
FST overexpression via global knock-in exhibited an impaired bone 
structure (27). However, in adult diabetic mice, FST was shown to 
accelerate bone regeneration by inhibiting myostatin-induced os-
teoclastogenesis (28). Furthermore, it has been reported that FST 
down-regulates BMP2-driven osteoclast activation (29). Therefore, 
the protective role of FST on obesity-associated bone remodeling, at 
least in part, may result from the neutralizing capacity of FST on 
myostatin in obesity. In addition, improvement in bone quality in 
FST mice may be explained by their enhanced muscle mass and 
strength, as muscle mass can dominate the process of skeletal adap-
tation, and conversely, muscle loss correlates with reduced bone 
quality (30).
Our results show that FST delivery mitigated pain sensitivity in 
OA joints, a critical aspect of clinical OA. Obesity and OA are asso-
ciated with both chronic pain and pain sensitization (31), but it is 
important to note that structure and pain can be uncoupled in OA 
Fig. 5. Effects of AAV-FST gene delivery on browning of WAT and mitochondrial OXPHOS. (A) Immunohistochemistry of UCP-1 expression in SAT. Scale bar, 50 m. 
(B) Western blotting of SAT for key proteins expressed in BAT, with -actin as a loading control. (C) Western blot analysis of mitochondria lysates from SAT for OXPHOS 
proteins using antibodies against subunits of complexes I, II, III, and IV and adenosine triphosphate (ATP) synthase. (D) Change of densitometry quantification normalized 
to the average FST level of each OXPHOS subunit. Data are presented as mean ± SEM; n = 3. *P < 0.05, t test comparison within each pair.
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(32), necessitating the measurement of both behavioral and struc-
tural outcomes. Of note, FST treatment protected only HFD animals 
from mechanical algesia at the knee post-DMM surgery and also 
rescued animals from pain sensitization induced by HFD in both 
the DMM and nonsurgical limb. The mitigation in pain sensitivity 
observed here with FST treatment may also be partially attributed 
to the antagonistic effect of FST on activin signaling. In addition to 
its role in promoting tissue fibrosis, activin A has been shown to 
regulate nociception in a manner dependent on the route of injec-
tion (33, 34). It has been shown that activin can sensitize the tran-
sient receptor potential vanilloid 1 (TRPV1) channel, leading to acute 
thermal hyperalgesia (33). However, it is also possible that activin may 
induce pain indirectly, for example, by triggering neuroinflammation 
(35), which could lead to sensitization of nociceptors.
The earliest detectable abnormalities in subjects at risk for devel-
oping obesity and type 2 diabetes are muscle loss and accumulation 
of excess lipids in skeletal muscles (4, 36), accompanied by impairments 
in nuclear-encoded mitochondrial gene expression and OXPHOS 
capacity of muscle and adipose tissues (17). PGC-1 activates mito-
chondrial biogenesis and increases OXPHOS by increasing the ex-
pression of the transcription factors necessary for mitochondrial 
DNA replication (37). We demonstrated that FST delivery can res-
cue low levels of OXPHOS in HFD mice by increasing expression 
PGC-1 (Fig. 3H). It has been reported that high-fat feeding results 
in decreased PGC-1 and mitochondrial gene expression in skeletal 
muscles, while exercise increases the expression of PGC-1 in both 
human and rodent muscles (38, 39). Although the precise molecu-
lar mechanism by which FST promotes PGC-1 expression has not 
been established, the infusion of lipids decreases expression of 
PGC-1 and nuclear-encoded mitochondrial genes in muscles (40). 
Thus, decreased lipid accumulation in muscle by FST overexpression 
may provide a plausible explanation for the restored PGC-1 in the 
FST mice. These findings were further confirmed by the metabolic 
profile, showing reduced serum levels of triglycerides, glucose, FFAs, 
and cholesterol (Fig. 1D), and are consistent with previous studies, 
demonstrating that muscles with high numbers of mitochondria and 
oxidative capacity (i.e., type 1 muscles with high levels of PGC-1 
expression) are protected from damage due to an HFD (4).
In addition, we found increased phosphorylation of protein ki-
nase B (Akt) on Ser473 in the skeletal muscle of FST-treated mice as 
compared to untreated HFD counterparts (Fig. 3K), consistent with 
restoration of a normal insulin response. A number of studies have 
demonstrated that the serine-threonine protein kinase Akt1 is a critical 
regulator of cellular hypertrophy, organ size, and insulin signaling 
(41). Muscle hypertrophy is stimulated both in vitro and in vivo by 
the expression of constitutively active Akt1 (42, 43). Furthermore, it 
has been demonstrated that constitutively active Akt1 also promotes 
the production of VEGF (44).
BAT is thought to be involved in thermogenesis rather than energy 
storage. BAT is characterized by a number of small multilocular 
adipocytes containing a large number of mitochondria. The process 
in which white adipose tissue (WAT) becomes BAT, called beiging 
or browning, is postulated to be protective in obesity-related in-
flammation, as an increase in BAT content positively correlates with 
increased triglyceride clearance, normalized glucose level, and re-
duced inflammation. Our study shows that AAV-mediated FST de-
livery serves as a very promising approach to induce beiging of WAT 
in obesity. A recent study demonstrated that transgenic mice over-
expressing FST exhibited an increasing amount of BAT and beiging 
in subcutaneous WAT with increased expression of key BAT-related 
markers including UCP-1 and PRDM16 (45). In agreement with 
previous reports, our data show that Ucp1, Prdm16, Pgc1a, and 
Cd167 are significantly up-regulated in SAT of mice overexpressing 
FST in both dietary interventions. FST has been recently demon-
strated to play a crucial role in modulating obesity-induced WAT 
expansion by inhibiting TGF-/myostatin signaling and thus pro-
moting overexpression of these key thermogenesis-related genes. 
Together, these findings suggest that the observed reduction in sys-
temic inflammation in our model may be partially explained by 
FST-mediated increased process of browning/beiging.
In conclusion, we show that a single injection of AAV-mediated 
FST, administered after several weeks of HFD feeding, mitigated the 
severity of OA following joint injury, and improved muscle perform-
ance as well as induced beiging of WAT, which together appeared 
to decrease obesity-associated metabolic inflammation. These find-
ings provide a controlled model for further examining the differential 
contributions of biomechanical and metabolic factors to the pro-
gression of OA with obesity or HFD. As AAV gene therapy shows 
an excellent safety profile and is currently in clinical trials for a 
number of conditions, such an approach may allow the development 
of therapeutic strategies not only for OA but also, more broadly, for 




All experimental procedures were approved by and conducted in 
accordance with the Institutional Animal Care and Use Committee 
guidelines of Washington University in Saint Louis. The overall 
timeline of the study is shown in fig. S1A. Beginning at 5 weeks of 
age, C57BL/6J mice (The Jackson Laboratory) were fed either Control 
or 60% HFD (Research Diets, D12492). At 9 week of age, mice re-
ceived AAV9-mediated FST or GFP gene delivery via tail vein injection. 
A total of 64 mice with 16 mice per dietary group per AAV group 
were used. DMM was used to induce knee OA in the left hind limbs 
of the mice at the age of 16 weeks. The non-operated right knees 
were used as contralateral controls. Several behavioral activities were 
measured during the course of the study. Mice were sacrificed at 
28 weeks of age to evaluate OA severity, joint inflammation, and 
joint bone remodeling.
Body weight and composition
Mice were weighed biweekly. The body fat content and BMD of the 
mice were measured using a DXA (Lunar PIXImus) at 14 and 26 weeks 
of age, respectively.
AAV gene delivery
Complementary DNA synthesis for mouse FST was performed by 
reverse transcriptase in a reverse transcription quantitative polymerase 
chain reaction (RT-qPCR) ( Invitrogen) mixed with mRNAs isolated 
from the ovary tissues of C57BL/6J mouse. The PCR product was 
cloned into the AAV9-vector plasmid (pTR-UF-12.1) under the 
transcriptional control of the chicken -actin (CAG) promoter in-
cluding cytomegalovirus (CMV) enhancers and a large synthetic 
intron (fig. S1B). Recombinant viral vector stocks were produced at 
Hope Center Viral Vectors Core (Washington University, St. Louis) 
according to the plasmid cotransfection method and suspension culture. 
Tang et al., Sci. Adv. 2020; 6 : eaaz7492     8 May 2020
S C I E N C E  A D V A N C E S  |  R E S E A R C H  A R T I C L E
9 of 11
Viral particles were purified and concentrated. The purity of AAV-
FST and AAV-GFP was evaluated by SDS–polyacrylamide gel elec-
trophoresis (PAGE) and stained by Coomassie blue. The results 
showed that the AAV protein components in 5 × 1011 vector genomes 
(vg) are only stained in three major protein bands: VR1, 82 kDa; VR2, 
72 kDa; and VR3, 62 kDa. Vector titers were determined by the DNA 
dot-blot and PCR methods and were in the range of 5 × 1012 to 
1.5 × 1013 vector copies/ml. AAV was delivered at a final dose of 
5 × 1011 vg per mouse by intravenous tail injection under red light 
illumination at 9 weeks of age. This dose was determined on the basis 
of our previous studies showing that AAV9-FST gene delivery by 
this route resulted in a doubling of muscle mass at a dose of 2.5 × 1011 vg 
in 4-week-old mice or at 5 × 1011 vg in 8-week-old mice (46).
Induction of OA by DMM
At 16 weeks of age, mice underwent surgery for the DMM to induce 
knee OA in the left hindlimb as previously described (2). Briefly, 
anesthetized mice were placed on a custom-designed device, which 
positioned their hindlimbs in 90° flexion. The medial side of the joint 
capsule was opened, and the medial meniscotibial ligament was tran-
sected. The joint capsule and subcutaneous layer of the skin were 
closed with resorbable sutures.
OA and synovitis assessment
Mice were sacrificed at 28 weeks of age, and changes in joint struc-
ture and morphology were assessed using histology. Both hindlimbs 
were harvested and fixed in 10% neutral-buffered formalin (NBF). 
Limbs were then decalcified in Cal-Ex solution (Fisher Scientific, 
Pittsburgh, PA, USA), dehydrated, and embedded in paraffin. The 
joint was sectioned in the coronal plane at a thickness of 8 m. Joint 
sections were stained with hematoxylin, fast green, and Safranin O 
to determine OA severity. Three blinded graders then assessed sec-
tions for degenerative changes of the joint using a modified Mankin 
scoring system (2). Briefly, this scoring system measures several as-
pects of OA progression (cartilage structure, cell distribution, integ-
rity of tidemark, and subchondral bone) in four joint compartments 
(medial tibial plateau, medial femoral condyle, lateral tibial plateau, 
and lateral femoral condyle), which are summed to provide a semi-
quantitative measure of the severity of joint damage. To assess the 
extent of synovitis, sections were stained with H&E to analyze infiltrated 
cells and synovial structure. Three independent blinded graders scored 
joint sections for synovitis by evaluating synovial cell hyperplasia, 
thickness of synovial membrane, and inflammation in subsynovial 
regions in four joint compartments, which were summed to provide 
a semiquantitative measure of the severity of joint synovitis (2). Scores 
for the whole joint were averaged among graders.
Serum and SF cytokine levels
Serum and SF from the DMM and contralateral control limbs were 
collected, as described previously (2). For cytokine and adipokine 
levels in the serum and SF fluid, a multiplexed bead assay (Discovery 
Luminex 31-Plex, Eve Technologies, Calgary, AB, Canada) was used 
to determine the concentration of Eotaxin, granulocyte colony- 
stimulating factor (G-CSF), granulocyte-macrophage CSF (GM-CSF), 
IFN-, IL-1, IL-1, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-9, IL-10, 
IL-12 (p40), IL-12 (p70), IL-13, IL-15, IL-17A, IP-10, keratinocyte 
chemoattractant (KC), leukemia inhibitory factor (LIF), liposaccharide- 
induced (LIX), monocyte chemoattractant protein-1 (MCP-1), M-CSF, 
monokine induced by gamma interferon (MIG), macrophage inflam-
matory protein–1 (MIP-1), MIP-1, MIP-2, RANTES, TNF-, and 
VEGF. A different kit (Mouse Metabolic Array) was used to measure 
levels for amylin, C-peptide, insulinotropic polypeptide (GIP), 
glucagon-like peptide-1 (GLP-1), ghrelin, glucagon, insulin, leptin, 
protein phosphatase (PP), peptide yy (PYY), and resistin. Missing 
values were imputed using the lowest detectable value for each analyte.
H&E and Oil Red O staining for muscle
Muscles were cryopreserved by incubation with 2-methylbutane in 
a steel beaker using liquid nitrogen for 30 s, cryoembedded, and 
cryosectioned at 8 m thickness. Tissue sections were stained following 
standard H&E protocol. Photomicrographs of skeletal muscle fiber 
were imaged under brightfield (VS120, Olympus). Muscle slides 
fixed in 3.7% formaldehyde were stained with 0.3% Oil Red O (in 
36% triethyl phosphate) for 30 min. Images were taken in bright-
field (VS120, Olympus). The relative concentration of lipid was de-
termined by extracting the Oil Red O with isopropanol in equally 
sized muscle sections and quantifying the OD500 (optical density at 
500 nm) in a 96-well plate.
Immunofluorescence labeling of FST expression
To determine spatial expression of FST in different tissues, cryosec-
tions of gastrocnemius muscles and adipose tissue were immuno-
labeled for FST. Tissue sections were fixed in 1.5% paraformaldehyde 
solution, and primary anti-FST antibody (R&D Systems, AF-669, 1:50) 
was incubated overnight at 4°C after blocking with 2.5% horse serum 
(Vector Laboratories), followed by labeling with a secondary anti-
body (Alexa Fluor 488, Invitrogen, A11055) and with 4′,6-diamidino- 
2-phenylindole (DAPI) for cell nuclei. Sections were imaged using 
fluorescence microscopy.
Imaging skeletal muscle using second-harmonic generation
Second-harmonic generation images of TA were obtained from un-
stained slices using backscatter signal from an LSM 880 confocal mi-
croscope (Zeiss) with Ti:sapphire laser tuned to 820 nm (Coherent). 
The resulting image intensity was analyzed using ImageJ software.
Bone microstructural analysis
To measure bone structural and morphological changes, intact 
hindlimbs were scanned by microCT (SkyScan 1176, Bruker) with 
an 18-m isotropic voxel resolution (455 A, 700-ms integration 
time, and four-frame averaging). A 0.5-mm aluminum filter was 
used to reduce the effects of beam hardening. Images were recon-
structed using NRecon software (with 10% beam hardening and 
20 ring artifact corrections). Subchondral/trabecular and cortical 
bone regions were segmented using CTAn automatic thresholding 
software. Tibial epiphysis was selected using the subchondral plate 
and growth plate as references. Tibial metaphysis was defined as the 
1-mm region directly below the growth plate. The cortical bone 
analysis was performed in the mid-shaft (4 mm below the growth 
plate with a height of 1 mm). Hydroxyapatite calibration phantoms 
were used to calibrate bone density values (mg/cm3).
Immunofluorescence detection of adipose tissue macrophages
Fresh visceral adipose tissues were collected, frozen in optimal cutting 
temperature compound (OCT), and cryosectioned at 5-m thickness. 
Tissue slides were then acetone-fixed followed by incubation with Fc re-
ceptor blocking in 2.5% goat serum (Vector Laboratories) and incubation 
with primary antibodies cocktail containing anti-CD11b:Alexa Fluor 488 
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and CD11c:phycoerythrin (PE) (BioLegend). Nuclei were stained 
with DAPI. Samples were imaged using fluorescence microscopy 
(VS120, Olympus).
Histology and immunohistochemistry for uncoupling 
protein 1
Adipose tissues were fixed in 10% NBF, paraffin-embedded, and cut 
into 5-m sections. Sections were deparaffinized, rehydrated, and 
stained with H&E. Immunohistochemistry was performed by incu-
bating sections (n = 5 per each group) with the primary antibody 
(anti–mUCP-1, U6382, Sigma), followed by a secondary antibody 
conjugated with horseradish peroxidase (HRP). Chromogenic sub-
strate 3,3′-diaminobenzidine (DAB) was used to develop color. 
Counterstaining was performed with Harris hematoxylin. Sections 
were examined under brightfield (VS120, Olympus).
Western blotting
Proteins of the muscle or fat tissue were extracted using lysis buffer 
containing 1% Triton X-100, 20 mM tris-HCl (pH 7.5), 150 mM 
NaCl, 1 mm EDTA, 5 mM NaF, 2.5 mM sodium pyrophosphate, 
1 mM -glycerophosphate, 1 mM Na3VO4, leupeptin (1 g ml−1), 
0.1 mM phenylmethylsulfonyl fluoride, and a cocktail of protease 
inhibitors (Sigma, St. Louis, MO, USA, catalog no. P0044). Protein 
concentrations were measured with Quick Start Bradford Dye 
Reagent (Bio-Rad). Twenty micrograms of each sample was sepa-
rated in SDS-PAGE gels with prestained molecular weight markers 
(Bio-Rad). Proteins were wet-transferred to polyvinylidene fluoride 
membranes. After incubating for 1.5 hours with a buffer containing 
5% nonfat milk (Bio-Rad #170-6404) at room temperature in 10 mM 
tris-HCl (pH 7.5), 100 mM NaCl, and 0.1% Tween 20 (TBST), mem-
branes were further incubated overnight at 4°C with anti–UCP-1 
rabbit polyclonal antibody (1:500, Sigma, U6382), anti-PRDM16 rabbit 
antibody (Abcam, ab106410), anti-CD137 rabbit polyclonal antibody 
(1:1000, Abcam, ab203391), total OXPHOS rodent western blot (WB) 
antibodies (Abcam, ab110413), anti-actin (Cell Signaling Technology, 
13E5) rabbit monoclonal antibody (Cell Signaling Technology, 4970), 
followed by HRP-conjugated secondary antibody incubation for 
30 min. A chemiluminescent detection substrate (Clarity, Western 
ECL) was applied, and the membranes were developed (iBrightCL1000).
Thermal hyperalgesia experiments
The effects of HFD and FST gene therapy on thermal hyperalgesia 
were examined at 15 weeks of age. Mice were acclimatized to all 
equipment 1 day before the onset of testing, as well as a minimum 
of 30 min before conducting each test. Thermal pain tests were 
measured in a room set to 25°C. Peripheral thermal sensitivity was 
determined using a hot/cold analgesia meter (Harvard Apparatus, 
Holliston, MA, USA). For hot plate testing, the analgesia meter was 
set to 55°C. To prevent tissue damage, a maximum cutoff time of 20 s 
was established a priori, at which time an animal would be removed 
from the plate in the absence of pain response, defined as paw with-
drawal or licking. Animals were tested in the same order three times, 
allowing each animal to have a minimum of 30 min between tests. 
The analgesia meter was cleaned with 70% ethanol between trials. 
The average of the three tests was reported per animal. To evaluate 
tolerance to cold, the analgesia meter was set to 0°C. After 1-hour 
rest, animals were tested for sensitivity to cold over a single 30-s 
exposure. The number of jumps counted per animal was averaged 
within each group and compared between groups.
Mechanical hyperalgesia
Pressure-pain tests were conducted at the knee using a Small Animal 
Algometer (SMALGO, Bioseb, Pinellas Park, FL, USA). Surgical and 
nonsurgical animals were evaluated over serial trials on the lateral 
aspect of the experimental and contralateral knee joints. The average 
of three trials per limb was calculated for each limb. Within each 
group, the pain threshold of the DMM limb versus non-operated limb 
was compared using a t test run on absolute values of mechanical 
pain sensitivity for each limb, P ≤ 0.05.
Treadmill run to exhaustion
To assess the effect of HFD and AAV-FST treatments on neuro-
muscular function, treadmill running to exhaustion (EXER3, Columbus 
Instruments) was performed at 15 m/min, with 5° inclination angle 
on the mice 4 months after gene delivery. Treadmill times were 
averaged within groups and compared between groups.
Forelimb grip strength test
Forelimb grip strength was measured using Chatillon DFE Digital 
Force Gauge (Johnson Scale Co.) for front limb strength of the ani-
mals. Each mouse was tested five times, with a resting period of 90 s 
between each test. Grip strength measurements were averaged within 
groups and compared between groups.
Measurement of cardiac function
Cardiac function of the mice was examined at 6 months of age 
(n = 3) using echocardiography (Vevo 2100 High-Resolution In 
Vivo Imaging System, VisualSonics). Short-axis images were taken 
to view the LV movement during diastole and systole. Transmitral 
blood flow was observed with pulse Doppler. All data and images were 
performed by a blinded examiner and analyzed with an Advanced 
Cardiovascular Package Software (VisualSonics).
Statistical analysis
Detailed statistical analyses are described in methods of each mea-
surement and its corresponding figure captions. Analyses were per-
formed using GraphPad Prism, with significance reported at the 95% 
confidence level.
SUPPLEMENTARY MATERIALS
Supplementary material for this article is available at http://advances.sciencemag.org/cgi/
content/full/6/19/eaaz7492/DC1
View/request a protocol for this paper from Bio-protocol.
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